| Recruiting | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanom NCT06319196 | University Health Network, Toronto | Phase 2 |
| Recruiting | Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) NCT06999980 | Melanoma Institute Australia | Phase 2 |
| Not Yet Recruiting | Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carbopla NCT07347444 | Fudan University | Phase 2 |
| Recruiting | Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery NCT07400302 | The First Hospital of Jilin University | Phase 2 |
| Recruiting | Neo-adjuvant Immunotherapy in Patients With Localized Melanoma NCT07230613 | UNICANCER | Phase 2 |
| Not Yet Recruiting | Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma NCT07236528 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| Recruiting | A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metas NCT07076550 | Alpha-9 Oncology USA Inc. | Phase 1 |
| Not Yet Recruiting | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma NCT06424626 | Peking University Cancer Hospital & Institute | Phase 1 |
| Withdrawn | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma NCT05545969 | Melanoma Institute Australia | Phase 2 |
| Terminated | Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Pro NCT05436990 | Yonsei University | Phase 2 |
| Completed | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma NCT05628883 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Withdrawn | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 NCT05482074 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery NCT05111574 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unre NCT05420324 | Eucure (Beijing) Biopharma Co., Ltd | Phase 2 |
| Recruiting | Axitinib and Nivolumab for the Treatment of Mucosal Melanoma NCT05384496 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Muco NCT04830124 | Mural Oncology, Inc | Phase 2 |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNM NCT05009446 | Eye & ENT Hospital of Fudan University | EARLY_Phase 1 |
| Completed | The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma NCT07506447 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Unknown | Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma NCT04622566 | Peking University Cancer Hospital & Institute | Phase 2 |
| Completed | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positiv NCT04551352 | Hoffmann-La Roche | Phase 1 |
| Active Not Recruiting | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With M NCT04645680 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucos NCT04472806 | Fudan University | Phase 2 |
| Unknown | Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study NCT04462965 | Peking University Cancer Hospital & Institute | Phase 2 |
| Unknown | Atypical MOLes and Melanoma Early Detection Study (MoleMed) NCT04353050 | Russian Academy of Medical Sciences | N/A |
| Unknown | Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma NCT04180995 | Peking University Cancer Hospital & Institute | Phase 2 |
| Unknown | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma NCT03986515 | Henan Cancer Hospital | Phase 2 |
| Active Not Recruiting | A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and Aft NCT03698019 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas NCT03611868 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Unknown | Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. NCT03602547 | AnewPharma | Phase 2 |
| Withdrawn | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High NCT03220009 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melano NCT03033576 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma NCT03241186 | Robert R. McWilliams, MD | Phase 2 |
| Completed | Molecular Characterization of Primary Mucosal Melanoma NCT03319693 | CHU de Reims | — |
| Terminated | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ip NCT02978443 | Georgetown University | Phase 2 |
| Unknown | The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by NCT03178123 | Shanghai Junshi Bioscience Co., Ltd. | Phase 2 |
| Completed | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases NCT02858869 | Emory University | Phase 1 |
| Completed | Neoadjuvant and Adjuvant Checkpoint Blockade NCT02519322 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists NCT02126579 | Craig L Slingluff, Jr | Phase 1 / Phase 2 |
| Completed | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV NCT02129075 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma NCT02158520 | Academic and Community Cancer Research United | Phase 2 |
| Completed | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma NCT01961115 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV NCT01166126 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era NCT03138642 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Dinaciclib in Treating Patients With Stage IV Melanoma NCT00937937 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma NCT00424515 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV NCT00110019 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma NCT00085189 | University of Southern California | Phase 2 |
| Completed | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patient NCT01989572 | National Cancer Institute (NCI) | Phase 3 |